Advanced disease with minimal remaining tissue: Limited peptide benefit potential
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds
This makes it valuable for both competitive athletes and recreational fitness enthusiasts
This regulatory activity may support endothelial function and promote vessel relaxation, contributing to improved hemodynamic balance in experimental settings